Surmodics | SRDX - Operating Profit


Surmodics reported $58K in Operating Profit for its fiscal quarter ending in June of 2025.





Operating Profit Change Date
Abbott USD 1.85B 399M Mar/2026
Align Technology USD 178.05M 46.66M Mar/2026
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD -141.26M 182.07M Mar/2026
Artivion USD 4.79M 6.85M Dec/2025
Baxter International USD 66M 280.2M Mar/2026
Boston Scientific USD 1.05B 190M Mar/2026
EDAP TMS EUR -4.92M 843K Sep/2025
Edwards Lifesciences USD 514.7M 144.4M Mar/2026
Haemonetics USD 67.4M 8.9M Dec/2025
Heron Therapeutics USD 38K 3.83M Dec/2025
J&J USD 6.62B 1.03B Mar/2026
Merit Medical Systems USD 44.16M 10.04M Mar/2026
Mesa Laboratories USD 5.78M 2.27M Dec/2024
Nektar Therapeutics USD -19.09M 15.26M Dec/2025
Option Care Health USD 72.54M 18.96M Mar/2026
Stryker USD 1.1B 867M Mar/2026
Surmodics USD 58K 5.7M Jun/2025
Trinity Biotech USD -509K 6.27M Sep/2025